Ryanodine receptor phosphorylation in human heart failure
Beard, N., Janczura, M, Dulhunty, A., Molenaar, P., & Laver, D. (2010) Ryanodine receptor phosphorylation in human heart failure. In Adelaide 2010 Joint AuPS/ASB Meeting, 28 November - 1 December 2010, National Wine Centre, Adelaide.
Heart failure is a complex disorder, characterized by activation of the sympathetic nervous system, leading
to dysregulated Ca2+ homeostasis in cardiac myocytes and tissue remodeling. In a variety of diseases, cardiac
malfunction is associated with aberrant fluxes of Ca2+ across both the surface membrane and the internal Ca2+
store, the sarcoplasmic reticulum (SR). One prominent hypothesis residues is that in heart failure, the activity of
the ryanodine receptor (RyR2) Ca2+ release channel in the SR is increased due to excess phosphorylation and
that this contributes to excess SR Ca2+ leak in diastole, reduced SR Ca2+ load and decreased contractility (Huke
& Bers, 2008). There is controversy over which serine residues in RyR2 are hyperphosphorylated in animal
models of heart failure and whether this is via the CaMKII or the PKA-linked signaling pathway. S2808, S2814
and S2030 in RyR2 have been variously claimed to be hyperphosphorylated. Our aim was to examine the degree
of phosphorylation of these residues in RyR2 from failing human hearts.
The use of human tissue was approved by the Human Research Ethics Committee, The Prince Charles
Hospital, EC28114. Left ventricular tissue samples were obtained from an explanted heart of a patient with endstage
heart failure (Emery Dreifuss Muscular Dystrophy with cardiomyopathy) and non-failing tissue was from
a patient with cystic fibrosis undergoing heart-lung transplantation with no history of heart disease. SR vesicles
were prepared as described by Laver et al. (1995) and examined with SDS-Page and Western Blot. Transferred
proteins were probed with antibodies to detect total protein phosphorylation, phosphorylation of RyR2 serine
residues S2808, S2814, S2030 and for the key proteins calsequestrin, triadin, junctin and FKBP12.6. To avoid
membrane stripping artifact, each membrane was exposed to one phosphorylation-specific antibody and signal
densities quantified using Bio-Rad Quantity One software.
We found no distinguishable difference between failing and healthy hearts in the protein expression levels
of RyR2, triadin, junctin or calsequestrin. We found an expected upregulation of total RyR2 phosphorylation in
the failing heart sample, compared to a matched amount of RyR2 (quantified using densiometry) in healthy
heart. Probing with antibodies detecting only the phosphorylated form of the specific RyR2 residues showed that
the increase in total RyR2 phosphorylation in the failing heart was due to hyperphosphorylation of S2808 and
S2814. We found that S2030 phosphorylation levels were unchanged in human heart failure. Interestingly, we
found that S2030 has a basal level of phosphorylation in the healthy human heart, different from the absence of
basal phosphorylation recently reported in rodent heart (Huke & Bers, 2008). Finally, preliminary results
indicate that less FKBP 12.6 is associated with RyR2 in the failing heart, possibly as a consequence of PKA
In conclusion, residues S2808 and S2814 are hyperphosphorylated in human heart failure, presumably
due to upregulation of the CaMKII and/or PKA signaling pathway as a result of chronic activation of the
sympathetic nervous system. Such changes in RyR2 phosphorylation are believed to contribute to the leaky
RyR2 phenotype associated with heart failure, which increases the incidence of arrhythmia and contributes to
the severely impaired contractile performance of the failing heart.
Huke S & Bers DM. (2008). Ryanodine receptor phosphorylation at serine 2030, 2808 and 2814 in rat
cardiomyocytes. Biochemical and Biophysical Research Communications 376, 80-85.
Laver DR, Roden LD, Ahern GP, Eager KR, Junankar PR & Dulhunty AF. (1995). Cytoplasmic Ca2+ inhibits
the ryanodine receptor from cardiac muscle. Journal of Membrane Biology 147, 7-22.
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Full-text downloadsdisplays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.
|Item Type:||Conference Item (Poster)|
|Keywords:||Ryanodine receptor, heart failure|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > CARDIOVASCULAR MEDICINE AND HAEMATOLOGY (110200)|
|Divisions:||Past > QUT Faculties & Divisions > Faculty of Science and Technology|
Current > Institutes > Institute of Health and Biomedical Innovation
Past > Schools > Pharmacy
|Copyright Owner:||Copyright 2010 Please consult the authors.|
|Deposited On:||31 Jan 2011 10:21|
|Last Modified:||11 Aug 2011 01:27|
Repository Staff Only: item control page